Literature DB >> 25083455

Alternative targeted therapy for early Her2 positive breast cancer.

Sandra L Harvey1, Mustafa Khasraw1.   

Abstract

Entities:  

Year:  2013        PMID: 25083455      PMCID: PMC4115726          DOI: 10.3978/j.issn.2227-684X.2013.02.06

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


× No keyword cloud information.
  14 in total

1.  HER2 genetic heterogeneity in breast carcinoma.

Authors:  Christian Ohlschlegel; Katharina Zahel; Doris Kradolfer; Margreth Hell; Wolfram Jochum
Journal:  J Clin Pathol       Date:  2011-10-19       Impact factor: 3.411

2.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

3.  Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Authors:  Paul E Goss; Ian E Smith; Joyce O'Shaughnessy; Bent Ejlertsen; Manfred Kaufmann; Frances Boyle; Aman U Buzdar; Pierre Fumoleau; William Gradishar; Miguel Martin; Beverly Moy; Martine Piccart-Gebhart; Kathleen I Pritchard; Deborah Lindquist; Yanin Chavarri-Guerra; Gursel Aktan; Erica Rappold; Lisa S Williams; Dianne M Finkelstein
Journal:  Lancet Oncol       Date:  2012-12-10       Impact factor: 41.316

4.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Authors:  Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbauer; Aron Goldhirsch; Michael Untch; Ian Smith; José Baselga; Christian Jackisch; David Cameron; Max Mano; José Luiz Pedrini; Andrea Veronesi; Cesar Mendiola; Anna Pluzanska; Vladimir Semiglazov; Eduard Vrdoljak; Michael J Eckart; Zhenzhou Shen; George Skiadopoulos; Marion Procter; Kathleen I Pritchard; Martine J Piccart-Gebhart; Richard Bell
Journal:  Lancet Oncol       Date:  2011-02-25       Impact factor: 41.316

5.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

6.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

7.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Authors:  Michael Untch; Sibylle Loibl; Joachim Bischoff; Holger Eidtmann; Manfred Kaufmann; Jens-Uwe Blohmer; Jörn Hilfrich; Dirk Strumberg; Peter A Fasching; Rolf Kreienberg; Hans Tesch; Claus Hanusch; Bernd Gerber; Mahdi Rezai; Christian Jackisch; Jens Huober; Thorsten Kühn; Valentina Nekljudova; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

8.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

9.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

10.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  B A Gusterson; R D Gelber; A Goldhirsch; K N Price; J Säve-Söderborgh; R Anbazhagan; J Styles; C M Rudenstam; R Golouh; R Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

View more
  1 in total

1.  Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.

Authors:  Cheng Wang; Yun-Hao Pan; Ming Shan; Ming Xu; Jia-Lin Bao; Li-Ming Zhao
Journal:  Int J Mol Sci       Date:  2015-03-02       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.